STUDY QUESTION: Does the amount of mitochondrial DNA (mtDNA) in blastocyst biopsy specimens have the potential to serve as a biomarker of euploid embryo implantation ability, independent of morphology?
Introduction
In order to maximize the efficiency of IVF treatment by reducing the number of unsuccessful embryo transfers, improved methods for the evaluation of embryo viability are required. While chromosome abnormalities are the most common cause of implantation failure and pregnancy loss, between a quarter and half of all euploid blastocysts fail to result in a viable pregnancy. In most cases, the reason for failure is unknown, but one possible explanation could be problems with cellular energy production (Van Blerkom et al., 1995; May-Panloup et al., 2003; Fragouli et al., 2015) . Factors such as metabolic rates and ATP content have been shown to vary significantly in oocytes and embryos and could conceivably impact viability. On this basis, it has been suggested that measurable differences in biological or chemical indicators of metabolic activity, or indeed variation in the number or function of mitochondria, may provide quantitative criteria for embryonic selection prior to transfer (Van Blerkom et al., 1995; Wilding et al., 2001) .
The mitochondrion is a membrane bound organelle existing within the cytoplasm of eukaryotic cells. Maternally inherited, mitochondria are unique in that they contain their own circular double stranded genome, spanning 16.6 kb in length and encoding 13 subunits of the respiratory chain complexes, essential for the production of ATP in the cell (Reynier et al., 2001; May-Panloup et al., 2003) . Mitochondria are often organized in a dynamic interwoven network, making their quantification technically difficult (Rube and van der Bliek, 2004) . Furthermore, individual organelles may contain more than one copy of the mitochondrial genome. Nonetheless, quantification of mitochondrial DNA (mtDNA) copy number by methods such as real-time PCR can provide a useful estimation of relative mitochondrial mass when individual samples of the same type are compared (Wu et al., 2002) .
Several groups have examined the mtDNA content of oocytes, some reporting that lower levels are associated with failed IVF cycles, aneuploidy and advancing reproductive age (e.g. Reynier et al., 2001; Konstantinidis et al., 2014) . There have also been reports of mtDNA content influencing fertilization potential (Chen et al., 1995; Van Blerkom et al., 1995; Steuerwald et al., 2000; Reynier et al., 2001) . The general conclusion from these studies is that more mitochondria and/ or mtDNA in oocytes is associated with superior clinical outcomes. A very recent study, examining cumulus cells, also suggests that higher mtDNA levels in these specialized, oocyte-associated cells may be linked to improved embryo quality (Desquiret-Dumas et al., 2017) .
While the mtDNA content of oocytes has been comparatively well studied, investigations into the relationship between mitochondria, their DNA, and the developmental potential of human preimplantation embryos are fewer in number (Wilding et al., 2003; Dumollard et al., 2009; Monnot et al., 2013; Diez-Juan et al., 2015; Fragouli et al., 2015) . Data from cleavage stage mtDNA quantity analysis and embryo implantation potential are contradictory. In a recent investigation carried out by our group, significant differences in mtDNA quantity and the ability of cleavage stage embryos to implant were not observed, although it should be noted that the number of embryos we assessed was relatively small (Fragouli et al., 2015) . In contrast, Diez-Juan et al. (2015) observed that implanting embryos had lower mtDNA levels. However, our study (Fragouli et al., 2015) and that of Diez-Juan (2015) were concordant in their conclusions that blastocysts with higher implantation potential have lower mtDNA quantities. In a recent, similar investigation, Victor et al. (2017) did not observe any link between mtDNA level and implantation. However, that study was hampered by variety of technical issues, which we believe render the results questionable. These will be addressed further below.
In the above-mentioned study, we were able to define a threshold level of mtDNA, above which the probability of implantation was greatly reduced (Fragouli et al., 2015) . The quantitative real-time PCR methodology used to establish this threshold was also validated using an independent methodological strategy, based upon next generation sequencing (NGS). It was therefore proposed that mtDNA quantities might represent a novel biomarker, which could be combined with preimplantation genetic testing for aneuploidy (PGT-A), assisting in the selection of viable IVF embryos for uterine transfer. To further evaluate the validity of the proposed viability threshold, and validate a slightly modified quantification strategy, we embarked on a large-scale, blinded, retrospective study of mtDNA levels. Moreover, we were able to examine the relationship between mtDNA quantities and several factors of known relevance to IVF outcomes. This investigation provides a further insight into the intricate relationship between mtDNA and implantation outcomes.
Materials and Methods

Ethical approval
This study involved a retrospective analysis on archived clinical samples and data obtained from patients referred to Reprogenetics for the purposes of PGT-A. The study was reviewed and approved through the Aspire Independent Review Board on 3 September 2015. Samples were analysed only after informed consent was given by the patients.
Patients and samples
The samples assessed during the course of this investigation consisted of surplus material leftover after routine PGT-A i.e. trophectoderm (TE) biopsy specimens each consisting of 5-10 cells, which had been subjected to whole genome amplification (WGA). Samples from a total of 1 505 blastocysts were assessed. The blastocysts were produced by 490 couples with an average female age of 34.7 years. These patients were being treated in 35 different IVF clinics located in the USA. All samples were deidentified prior to initiation of this study.
Sample acquisition and comprehensive chromosome screening
Embryo micromanipulation, biopsy and preparation of TE samples were as described previously (Fragouli et al., 2013a,b) . The DNA of TE samples was subjected to WGA using SurePlex (Illumina, USA) followed by comprehensive chromosome screening via aCGH using 24Sure (Illumina, USA) or via NGS (VeriSeq) (Illumina, USA) according to the manufacturers' instructions Gutiérrez-Mateo et al., 2011; Magli et al., 2011; Wells et al., 2014; Fiorentino et al., 2014a,b; Maxwell et al., 2016) . The results obtained were analysed using BlueFuse Multi v4.1 software at a single PGD laboratory. Outcome data were collected as part of routine follow-up.
mtDNA quantification mtDNA was assessed in WGA products of blastocysts, which were classified as euploid with aCGH or NGS, using a modified version of our previously described protocol (Fragouli et al., 2015) . Specifically, two separate customdesigned TaqMan assays (ThermoFisher, USA) targeting distinct mtDNA sites were used, to increase the accuracy of the assay. The first was as described previously (16 s RNA; Fragouli et al., 2015) , whereas the second targeted an mtDNA sequence on the opposite side of the circular mitochondrial genome (MajArc probe sequence, CTGTTCCCCAACCTTTTCCT). A separate threshold was established for each of the two TaqMan assays. These were 0.0004 for the mitochondrial 16 s ribosomal RNA sequence (Fragouli et al., 2015) and 0.000335 for the MajArc sequence. Details on mitochondrial sequence selection/TaqMan assay design and threshold establishment are described below. In order for a sample to be classified as having 'elevated' mtDNA quantities, both assays needed to be above these thresholds. Samples were analysed in triplicate using the Viia7 real-time PCR machine (ThermoFisher, USA). As previously described (Fragouli et al., 2015) , a nuclear multicopy Alu sequence was used as an internal standard, allowing normalization of data within samples, controlling for differences in PCR efficiency and number of cells in the biopsy specimen. Additionally, every amplification experiment included previously quantified DNA samples, acting as a reference for the purposes of maintaining consistency across different runs.
Mitochondrial TaqMan assay design
Both the 16 s RNA (Fragouli et al., 2015) TaqMan assay, as well as the MajArc assay, underwent analysis (BLAST) to establish the uniqueness of primer and probe sequences within the genome. The analysis confirmed that there were no areas in the nuclear genome (such as nuclear pseudogenes) with sufficient homology for detection using these assays and that any sequences detected should be confined to the mitochondrial genome. TaqMan assays are particularly resistant against the inadvertent detection of unintended sequences. Sequence detection not only involves the annealing of primers designed such that the chances of off-target amplification are minimized, as would be standard for any PCR-based protocol, but also the additional hybridization of a sequence detection probe. Amplified sequences are only detected if the probe also hybridizes, adding an additional layer of stringency. We specifically chose this quantification strategy using TaqMan assays, rather than a generic DNA stain such as SYBR green, because of the increased specificity that such an approach allows.
Threshold establishment
In order to establish the mtDNA quantity threshold for the new TaqMan assay (MajArc), and evaluate the threshold for the previously used TaqMan assay (16 s RNA), we analysed a total of 137 TE samples which had been characterized as low/normal with the protocol described in Fragouli et al. (2015) and 30 TE samples which were characterized as elevated. All corresponding embryos had been transferred, and none of the 30 embryos with elevated mtDNA had led to ongoing pregnancies. Assessment of these samples with known mtDNA quantities allowed the establishment of thresholds for the two TaqMan assays. A revalidation of thresholds was needed due to technical changes in the laboratory, most notably a switch from using a StepOne Real-Time PCR System (ThermoFisher, UK), which was used in all initial work, to a Viia7 real-time PCR machine (ThermoFisher, USA). Different PCR machines have different temperature ramping speeds and varying probe detection sensitivities. The change in quantification equipment led to an alteration in mtDNA quantity thresholds for the previously used TaqMan assay (16 s RNA) from 0.003 (Fragouli et al., 2015) to 0.0004.
Normalization and performance comparison of multicopy and single-copy nuclear sequences during quantitative real-time PCR
The real-time PCR results from the two mtDNA loci were normalized against results from various nuclear DNA sequences (a multicopy Alu sequence, 9 individual single-copy loci, or an average of the 9 single-copy sequences). The choice of a multicopy nuclear DNA sequence (Alu) as an internal control was made in order to minimize the impact of DNA amplification problems that affect individual loci, principally allele dropout (ADO). However, we also explored the use of single-copy nuclear gene sequences as an internal reference. As well as amplifying the two mtDNA sequences and the Alu repeats, we also amplified and quantified a total of nine different single-copy nuclear DNA sequences. These included the following loci: TMCO4 (TaqMan assay ID Hs00876448_cn, cytoband 1p36.13), IAH1 (TaqMan assay ID Hs04658573_cn, cytoband 2p25.1d), NGLY1 (TaqMan assay ID Hs01278165_cn, cytoband 3p24.2a), SRD5A1 (TaqMan assay ID Hs02178036_cn, cytoband 5p15.31c), C10orf90 (TaqMan assay ID Hs07226388_cn, cytoband 10q26.2a), FAM160A2 C11orf42 (TaqMan assay ID Hs01644358_cn, cytoband 11p15.4c), GOLGA3 (TaqMan assay ID Hs01436960_cn, cytoband 12q24.33d), TMEM179 (TaqMan assay ID Hs02277899_cn, cytoband 14q32.33b) and FAM169B (TaqMan assay ID Hs02820990_cn, cytoband 15q26.3a). Calculations of mtDNA quantities were made with reference to each of the nuclear loci individually. Additionally, mtDNA quantities were referenced against an average derived from the nine single-copy genes and also against Alu. Data normalization took place as described in Fragouli et al. (2015) .
Comparison relative to pregnancy outcomes
Implantation predictions were made based on mtDNA quantities. Pregnancy outcomes (where available) were blinded to the analyst at the time of mtDNA assessment and decoded at a later date by an individual without any other involvement in the study.
Statistical analysis
Statistical analysis of data was conducted using Fisher's exact test, the Student's t-test and ANOVA. A P-value < 0.05 was considered to be statistically significant with P < 0.001 indicating high significance.
Results
The use of multicopy versus single-copy nuclear sequences for the accurate calculation of mtDNA quantities
The use of nine individual single-copy nuclear loci for normalization was attempted on 230 euploid TE samples, which were previously subjected to WGA. Inconsistencies could be clearly visualized when plotting normalized mtDNA results obtained using one nuclear locus against those calculated for the same samples but using a different nuclear locus for normalization (Fig. 1) . In contrast, averaging the data together from all nine single-copy nuclear loci, and using that as a reference, provided results concordant with normalization achieved using the multicopy Alu sequence. It is clear from these results that singlecopy sequences cannot be used for accurate quantification of DNA in TE biopsy specimens. This is in line with expectations as detailed in Supplementary data, Fig. S1 .
mtDNA quantities in examined TE samples
A total of 1 505 TE samples were examined during the course of this study, biopsied from blastocysts produced in 35 different IVF clinics. All corresponding embryos had been classified as euploid either via Figure 1 Comparison of mitochondrial DNA (mtDNA) results normalization against a multicopy nuclear DNA sequence (Alu) and also against different single-copy nuclear genes. A total of 230 euploid trophectoderm (TE) samples which were previously subjected to whole genome amplification were examined. Representative results are shown after normalization using two of the single-copy genes (TMEM179 and TMCO4) compared to results normalized using Alu (a and b). While Alu-normalized data and single gene-normalized data follow a similar trend, significant levels of variation are evident. mtDNA quantification when data normalized with one single-copy nuclear gene (TMEM179) was compared against data normalized with a different single-copy gene (FAM160A2 C11orf42), demonstrating that concordance is poor (c). If, however, the values from the nine distinct single-copy nuclear genes were averaged together and then used for normalization, the results were much closer to those obtained using Alu (d) . This demonstrates that accurate normalization of mtDNA data can only be accomplished using a multicopy nuclear sequence, either by employing the combined data of multiple individual loci or by utilizing a naturally occurring multicopy sequence, such as Alu. The fact that very similar mtDNA quantification results were obtained regardless of whether normalization was undertaken using Alu or the averaged results of nine single-copy genes, also demonstrates that variation in the number of Alu repeats between individuals has little effect on measurement of relative mtDNA levels. aCGH or NGS. Quantification of mtDNA was successful in all cases (1 505/1 505, 100%). The vast majority (1 366 or 90.8%) of these TE samples were classified as having low mtDNA levels (i.e. typical amounts of mtDNA, below the established thresholds), correlated with a good chance of embryo implantation. The remaining 139 (9.2%) TE samples were classified as having elevated mtDNA levels (i.e. above established thresholds), associated with reduced capacity for implantation.
Relationship between referring clinic and referral reasons and mtDNA quantities When assessing average mtDNA quantities for the 35 clinics that contributed samples, no significant differences were observed for either of the two mitochondrial assays. However, we did observe that certain clinics had a greater percentage of their embryos displaying elevated mtDNA levels compared to others. The total number of embryos per clinic investigated, as well as the total number of embryos with low and elevated mtDNA levels are summarized in Table I , and illustrated in Fig. 2 .
We also carried out a comparative analysis of reason for PGT-A referral and mtDNA levels. It was evident from the results obtained during this evaluation that there were no significant differences between PGT-A indication and mtDNA quantities in euploid blastocysts (P = 0.99, t-test). These data are summarized in Table II. mtDNA quantities are independent of embryo morphology and embryo sex Morphological criteria remain the predominant factors used for the selection of IVF embryos for transfer to the uterus. It was therefore of interest to investigate potential relationships between variation in mtDNA quantities and different aspects of morphology. A subset of 299 euploid blastocysts, for which morphological data were available, was examined for this purpose. Of these blastocysts, 276 had mtDNA levels below the established thresholds, while the remaining 23 had elevated mtDNA levels. Data analysis did not detect any correlations between the morphological criteria examined and the levels of mtDNA observed in these two groups. Specifically, no statistically significant differences were observed between the number of euploid blastocysts with low and elevated mtDNA according to expansion grade (grades 5-6 versus 3-4 P = 0.6526; grade 5-6 versus 'early' blastocysts P = 0.1726; grade 3-4 versus 'early' P = 0.2488). Similarly, no differences were seen in embryos with low and elevated mtDNA levels related to either ICM or TE grade (ICM grade A versus ICM grade B P = 0.5829; ICM grade A versus ICM grade C P = 0.1175; ICM grade B versus ICM grade C P = 0.1592; TE grade A versus TE grade B P = 0.1431; TE grade A versus TE grade C P = 1.0000; TE grade B versus TE grade C P = 0.3290). No significant relationship was observed between the incidence of blastocysts with low mtDNA versus those blastocysts with elevated mtDNA and the day upon which biopsy took place (Day-5 versus Day-6 P = 0.2490, Day-5 versus Day-7 P = 0.1783, Day-6 versus Day-7 P = 0.1085). Given these results, it was concluded that elevated mtDNA quantities were independent of embryo morphology. These results are outlined in Table III. We also examined the presence of a possible relationship between the sex of the embryo and mtDNA quantity. We did not observe any significant differences in mtDNA levels between male and female embryos (P = 0.2442 for first mitochondrial assay and P = 0.97 for second mitochondrial assay, t-test, Fig. 3 ).
Relationship between female age and mitochondria DNA quantities
The relationship between mtDNA levels in TE specimens and female age at the time of treatment was also considered. The patient population had an average female age of 34.7 years (range: 21-48 years). The values from the mitochondrial assays were divided across different age groups, in order to examine the distribution of mtDNA quantities by female age (Table IV) . As seen in Fig. 4 , female patients in the youngest age bracket (21-22 years) had average mtDNA levels that were significantly lower than those in the oldest age bracket (42-48 years) (P = 0.0038 for first mitochondrial assay and P = 0.0105 for second mitochondrial assay, t-test). No significant differences in mtDNA quantities were observed within intermediate age ranges.
While average mtDNA levels differed at the extremes of the age range, the incidence of embryos having quantities of mtDNA levels considered to be 'elevated' did not. In total, 13.6% (205/1 505) of all samples were produced by oocyte donors (average age 25.5 years) and 10.2% (21/205) had mtDNA levels above the established thresholds, a percentage very similar to that observed in the population as a whole (10.2% versus 9.2% overall, P = 0.39). This suggests that blastocysts with elevated quantities of mtDNA are equally common in young fertile patients and older patients undergoing infertility treatment. 
Table II
Number of euploid blastocysts with low (normal) mtDNA levels and euploid blastocysts with elevated mtDNA levels in relation to indication for preimplantation genetic testing for aneuploidy (PGT-A) or PGD.
PGT-A or PGD indication
Total euploid blastocysts examined Total euploid blastocysts with low mtDNA levels (%)
Total euploid blastocysts with elevated mtDNA levels (%) Transfer of euploid blastocysts with low mtDNA levels may help to enhance selection of viable embryos
At the time of analysis, pregnancy outcome data were available for 282 of the embryos assessed. Of these embryos, 185 were associated with a successful pregnancy, giving an ongoing pregnancy rate of 65.6% (185/282). Of the 282 embryos, 249 were classified as having low/ normal levels of mtDNA and were therefore predicted to have a higher chance of implanting, while 33 contained elevated levels of mtDNA and were therefore not expected to implant. Comparison of the mtDNA predictions with actual outcome data confirmed that none of the 33 embryos with elevated mtDNA levels produced a pregnancy, giving an implantation rate that differed markedly from the population as a whole (P < 0.0001). Embryos with low/normal levels of mtDNA were associated with an implantation rate of 74.3% (185/249), which was significantly higher than the overall cohort of embryos (P = 0.030). These results are shown in Fig. 5 .
Discussion
This blinded retrospective analysis of the ability of mtDNA quantification to predict embryo implantation potential demonstrated a 100% negative predictive value. Of the 33 embryos identified as containing 'elevated' amounts of mtDNA, none implanted. In contrast, 74.3% of embryos containing amounts of mtDNA in the normal range led to pregnancies. These results provide strong support for the hypothesis that mtDNA quantification, if carried out using appropriate, validated methods, can be used as a biomarker for the identification of a subset of blastocysts that are nonviable despite being chromosomally normal. While average mtDNA levels displayed some small but significant differences in association with other variables evaluated during this study, the phenomenon of elevated mtDNA (i.e. exceeding defined thresholds) showed no links with referral reason, patient age or embryo morphology.
The importance of using a carefully designed and validated method for mtDNA analysis cannot be overstated. Recently, articles have appeared in the literature, attempting to draw conclusions about the value of mtDNA quantification using methodologies that have technical limitations and/or misconceptions that preclude an accurate measurement (Victor et al., 2017) . Important problems include the following: (i) application of NGS techniques, such as the widely used VeriSeq PGS method, which are known to provide insufficient coverage of the mitochondrial genome for a statistically robust quantification (i.e. inadequate numbers of mtDNA reads); (ii) utilization of methods that aim to put a precise figure on the number of mtDNA molecules in the sample (an approach known as absolute quantification), but failing to account for sample-to-sample variability in the efficiency of WGA or differences in the number of cells in each biopsy specimen, each of which greatly affect the amount of mtDNA detected; and (iii) use of a single-copy nuclear gene for data normalization, which as this study clearly shows produces data so distorted by ADO as to be almost meaningless (see Supplementary data, Fig. S1 ). Some authors have suggested that when mtDNA normalization involves data from multiple sites interspersed throughout the nuclear genome (e.g. Alu), an adjustment should be made to take into account differences in chromosome copy number (Victor et al., 2017) . While this is not an unreasonable idea, it should be noted that if the specimen is chromosomally normal, as was the case for all of the samples in the current study, differences in total DNA content have very little impact on the quantification of mtDNA. The only variation in DNA content observed in euploid specimens is that between males (having one X-and one Y-chromosome) and females (with two X-chromosomes), representing a difference of just 1.58%. This pales into insignificance when compared to the much greater distortions caused by the three problems listed above. Adjusting for sex (XX versus XY) differences would not have led to reclassification of any of the samples in the data set reported here.
Interestingly, although average mtDNA quantities were fairly consistent between different clinics, embryos classified as having elevated mtDNA levels were more common in some centers than others. Indeed, in some clinics few, if any, affected embryos were observed. The explanation for this clinic to clinic variation is not known at this time (indeed the underlying biological reason for elevated mtDNA in general is not yet understood). However, it is conceivable that the phenomenon is associated with cellular stress and could be influenced by factors such as the choice of culture medium, the quality of the incubator, gas composition, extent of embryo handling (e.g. number of times the embryo is taken out of the incubator for observation, media changes, etc.), or even differences in hormonal stimulation regimens. It is also possible that patient-specific factors could influence the frequency of elevated mtDNA levels, although this seems less likely as our analysis indicates that the phenomenon is not associated with specific indications for PGT-A (P = 0.99) and embryos with high quantities of mtDNA are seen at a similar frequency in all cycles, including those involving oocyte donors.
The relationship between mtDNA quantity and female age was further investigated during the course of this study. The obtained results suggested that, on average, blastocyst mtDNA quantities rise with age, although this association could only be clearly seen when comparing the extremes of the age range. The possibility that blastocyst mtDNA levels might show a tendency to increase with advancing female age has been suggested previously in a smaller study (Fragouli et al., 2015) . Previous studies have shown that standard morphological evaluations carried out in IVF clinics cannot provide a reliable prediction of blastocyst chromosome status (e.g. Munné et al., 2007; Alfarawati et al., 2011; Fragouli et al., 2013a,b) . However, a weak association between aneuploidy and reduced morphological grade has been noted. Chromosome errors are less common in blastocysts of good morphology, while aneuploidy, especially types involving multiple chromosome abnormalities, are overrepresented among embryos with the poorest morphological scores Fragouli et al., 2013a,b) . In the current study, attempts were made to identify relationships between different aspects of blastocyst Figure 4 Relative mtDNA quantities (a for mtDNA assay 1 and b for mtDNA assay 2) observed in TE samples removed from blastocysts generated by women in the youngest age group (21-22 years) and those generated by women in the oldest age group (42-28 years). The older age group blastocysts had significantly more mtDNA (P = 0.00384 for mtDNA assay 1 and P = 0.0105 for mtDNA assay 2) compared to the younger age group blastocysts.
Relative quantity of mtDNA-assay 1
Ongoing clinical pregnancy
No viable pregnancy established
Ongoing clinical pregnancy
No viable pregnancy established
Relative quantity of mtDNA-assay 2 Figure 5 All of the 33 euploid blastocysts identified to have mtDNA quantities above thresholds established for two different sites on the mitochondrial genome failed to implant. Hence, the negative predictive value of mtDNA selection was 100%.
morphology and mtDNA content. Neither expansion grade, ICM and TE morphology, nor the day at which biopsy was carried out were associated with alterations in the incidence of embryos having elevated mtDNA levels. This analysis makes it clear that increased amounts of mtDNA, associated with implantation failure, provide information on viability which is independent of that obtained by evaluating morphological characteristics. This conclusion is further emphasized by the fact that the 33 euploid blastocysts with elevated mtDNA levels and known clinical outcomes were all of good morphological grade. None led to an ongoing pregnancy. The apparent independence of elevated mtDNA levels with respect to other patient/embryo characteristics, especially those currently employed for embryo selection (e.g. chromosomal constitution and morphology), makes this feature potentially interesting for blastocyst viability assessment. The very different clinical outcomes for embryos with/without elevated mtDNA provide strong evidence that the form of embryo assessment described in this study could be a useful adjunct to PGT-A, significantly improving IVF outcomes by helping to distinguish embryos of exceptional implantation potential from a subset of blastocysts that have little or no chance of forming a pregnancy. Variation in the incidence of affected embryos in different IVF clinics means that the value of this form of embryo selection will not be the same in all centers. However, the current data suggest that, on average,~10% of euploid blastocysts have elevated mtDNA and that the phenomenon is associated with about one-third of implantation failures affecting chromosomally normal blastocysts.
The reason why some nonviable blastocysts exhibit elevated mtDNA levels is still unclear. After fertilization the oocyte's mitochondria are asymmetrically segregated (Van Blerkom et al., 2000; Murakoshi et al., 2013) among the newly formed blastomeres, without any new replication taking place (St John, 2014) . mtDNA replication is thought to start again after blastocyst formation, initially in the TE of the embryo (St John, 2014) . It is possible that blastocysts with elevated mtDNA levels are experiencing some form of cellular stress, and require additional energy as they attempt to resolve the problem. They could conceivably increase the rate at which new mitochondria are produced or reduce the rate of mitophagy, allowing persistence of organelles that would usually be eliminated. A hypothesis centered on stress is in line with our previous finding that, on average, aneuploid embryos have significantly more mtDNA compared to euploid ones (Fragouli et al., 2015) . If elevated mtDNA is associated with increased ATP production, which has not been demonstrated thus far, our results could also be potentially compatible with the 'quiet embryo hypothesis', as proposed by Leese, which suggests that a viable embryo has a relatively lower or 'quiet' metabolism, whereas those under stress, and of reduced developmental potential, tend to be metabolically more active (Leese, 2002 ). An alternative hypothesis is that an increase in mitochondria (and mtDNA) represents a compensatory mechanism, employed when the existing mitochondria are not functioning properly. Studies assessing ATP production in blastocysts with unusually elevated mtDNA could provide an insight into the energy status of such embryos and help reveal which hypothesis is the more likely.
The impact of mtDNA quantity on embryo viability, described in the current investigation, as well as those reported previously in smaller studies, are encouraging (Diez-Juan et al., 2015; Fragouli et al., 2015; Spinella et al., 2016) . Nonetheless, it would be beneficial if the usefulness of blastocyst mtDNA measurement could be investigated further using other study designs, such as blinded non-selection clinical trials, double transfer studies (e.g. our ongoing ClinicalTrials.gov study # NCT02673125, which involves transfer of a blastocyst with low mtDNA levels along with a sibling embryo with elevated mtDNA levels), and/or randomized controlled trials. However, in order to properly evaluate the efficacy of embryo selection based upon mtDNA quantification, it is critical that such studies use well-validated protocols and ideally involve IVF cases derived from several distinct centers. Further investigation into the biological mechanisms that lead to an increase in mtDNA levels for some embryos will be important to aid our understanding of this as yet unexplained phenomenon.
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